针对TRIP13克服抗癌药物耐药性的目标 (综述)
Liwen Zhao1, Siyu Ye1, Shengnan Jing1
1Institute of Pain Medicine and Special Environmental Medicine, Co‑innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu 226019, P.R. China.
Oncology reports
|October 6, 2023
概括
甲状腺激素受体相互作用因子13 (TRIP13) 通过破坏细胞分裂和修复,驱动癌症药物耐药性. 抑制TRIP13是一种有希望的策略,可以在癌症治疗中克服治疗耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 癌症仍然是人类健康的主要威胁,耐药性严重阻碍有效治疗.
- 甲状腺激素受体交互因子13 (TRIP13),AAA+ ATPase,与促进癌症治疗耐药性有关.
- TRIP13介导的抗癌药物耐药性的精确分子机制尚未完全理解.
研究的目的:
- 研究TRIP13表达在抗癌药物耐药性中的作用.
- 探索潜在的治疗策略来克服TRIP13驱动的耐药性.
- 阐明TRIP13赋予抗癌药物耐药性的分子机制.
主要方法:
- 文献综述和对有关TRIP13在癌症中的功能现有研究的分析.
- 探索TRIP13参与线粒检查点功能障碍,DNA修复,自和免疫逃避.
- 讨论涉及TRIP13抑制剂的组合疗法.
主要成果:
- TRIP13表达是抗癌药物耐药性的发展的一个关键因素.
- 通过包括线粒检查点功能障碍,增强DNA修复,增加自和逃避免疫清除在内的机制,TRIP13促进抵抗.
- 针对TRIP13的组合治疗与其他抑制剂一起显示出克服耐药性的潜力.
结论:
- TRIP13是抗癌药物耐药性的关键媒介.
- 针对 TRIP13 提出了一个可行的治疗策略,以改善癌症治疗结果.
- 对TRIP13抑制剂和组合疗法的进一步研究是有必要的,以增强目前的抗癌选择.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
01:10Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K